GlassScriptPhysician profile
Benjamin N Cheyette
NPI 1093733198
$2,946.78
in general payments reported to CMS, 2019-2025
19 companies · $674 in 2025
The $674 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $701 · 2022: $229 · 2023: $673 · 2024: $669 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $591.40 | 2021-2025 | Vraylar |
| Lundbeck LLC | $408.26 | 2021-2025 | Rexulti |
| Tris Pharma INC | $395.16 | 2021-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $249.11 | 2023-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $217.53 | 2023-2025 | Spravato |
| Neurocrine Biosciences, INC. | $177.18 | 2021-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $165.19 | 2021-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.96 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $100.37 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $91.30 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $75.61 | 2021-2024 | Rexulti, Abilify Maintena |
| Bausch Health US, LLC | $72.85 | 2021-2023 | Aplenzin |
| Supernus Pharmaceuticals, INC. | $51.62 | 2022-2024 | Qelbree, Qelbree |
| Corium, LLC | $46.69 | 2022 | |
| Noven Therapeutics, LLC | $42.18 | 2024 | Secuado, Xelstrym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $30.65 | 2021 | |
| Alkermes, INC. | $24.00 | 2023 | Aristada, Lybalvi |
| Alfasigma USA, INC. | $22.09 | 2022 | |
| Ironshore Pharmaceuticals INC. | $20.63 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Cheyette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.